Technology ID
TAB-2703
Nucleic Acid-based Compositions and Methods for the Species-Specific Detection of Pathogenic Candida Fungi
E-Numbers
E-340-2013-0
Lead Inventor
Lott, Timonthy (CDC)
Co-Inventors
Elie, Cheryl (CDC)
Morrison, Christine (CDC)
Reiss, Errol (CDC)
Applications
Therapeutics
Research Materials
Occupational Safety and Health
Diagnostics
Consumer Products
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Development Stages
Pre-Clinical (in vitro)
Development Status
In vitro data available
Lead IC
CDC
ICs
CDC
This invention pertains to the development of oligonucleotides for the rapid nucleic acid-based identification of the Candida fungi species C. haemulonii, C. kefyr, C. lambica, C. lusitaniae, C. norvegensis, C. norvegica, C. rugosa, C. utilis, C. viswanathii, C. zeylanoides, C. dubliniensis, and C. pelliculosa within biological samples. This identification is accomplished by the targeting the internally transcribed spacer-2 (ITS2) region that are specific for each species. The assay is sensitive, specific and rapid. Implementation of the technology will facilitate earlier specific diagnoses, and lead to better antifungal therapy implementation for infected patients.
Commercial Applications
- Directing antifungal drug therapy for improved patient outcomes
- Detection, discrimination of Candida species from biological samples
- Addressing secondary infections of immunosuppressed individuals
Competitive Advantages
- Easily adapted for use in kits
- High-throughput capable
- Rapid and cost-effective
Licensing Contact: